Sonio, the medtech company specializing in women’s and children’s health, has officially been acquired by Samsung Medison, a global medical equipment company affiliated with Samsung Electronics, following the approval of the French Ministry of the Economy and Finance. This acquisition marks a significant milestone in the global expansion of Sonio’s innovative healthcare solutions, aimed at enhancing maternal and child health worldwide.
The acquisition follows a series of successful developments for Sonio, including a second wave of FDA clearance in 2024 and the deployment of its AI-powered reporting and workflow solution in multiple sites across the United States. Sonio’s technology, designed to assist clinicians in the evaluation and documentation of obstetrics and gynecology ultrasound exams, has gained recognition for its ability to streamline workflows and enhance the quality of prenatal care.
In May 2024, Samsung Medison had announced the signing of an acquisition agreement valued at 85 million euros, a deal that was subject to approval by the French Ministry of the Economy and Finance. Today, the acquisition has been officially approved, granting Samsung Medison 100% ownership of Sonio.
Cécile Brosset, CEO and Co-founder of Sonio, commented, “Alongside Samsung Medison, we are excited to make significant strides in the maternal care industry. In addition, Sonio plans to continue to advance medical reporting technology and diagnostic software globally, including for underserved areas in healthcare.”
Founded in 2020, Sonio has been at the forefront of leveraging AI to improve women’s and children’s health globally. Supported by early investors such as Elaia, BpiFrance, OneRagtime, Cross Border Impact Ventures, and the EIC Fund, Sonio’s technology has become a crucial tool for clinicians, particularly in the field of obstetrics and gynecology.
Samsung Medison’s CEO, Kyu Tae Yoo, stated: “With the workforce shortages affecting the global healthcare industry, the real-time ultrasound exam guidance and quality assurance developed by Sonio is becoming more relevant to ensure high-quality care. We look forward to combining Sonio’s and Samsung’s advanced engineering to enhance our ultrasound roadmap and introduce next-generation AI technologies to the market. We will focus on innovations designed to enhance exam quality, efficiency, and ultimately improve patient care.”
As Sonio integrates into Samsung Medison’s operations, it will continue its commercial growth independently, maintaining its commitment to developing products and services compatible with all ultrasound device manufacturers. Brosset reaffirmed this commitment, saying, “We are committed to supporting all healthcare providers and patients as we pursue our mission of providing equal access to high-end technology and quality maternal healthcare globally.”
This acquisition not only strengthens Sonio’s position in the healthcare market but also underscores the growing importance of AI-driven solutions in addressing the challenges faced by healthcare providers worldwide. As Sonio and Samsung Medison join forces, the future of maternal and child health looks increasingly promising, with the potential for significant advancements in care quality and accessibility.
